Labstyle Innovations Corp. (DRIO) 0.3800 $DRIO
LabStyle Innovations Announces 2015 First Quarter Results
PR Newswire - Fri May 15, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, reported its financial and operational results for the three-month period ended March 31, 2015 and provided an update on recent corporate achievements.
LabStyle Innovations Receives Health Canada Approval for Commercialization of the Dario Diabetes Management Solution
PR Newswire - Thu May 14, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, has announced today that it has been granted Health Canada approval to market and sell Dario(TM) in Canada through their exclusive distributor in Canada Auto Control Medical Inc. ("ACM"
. ACM is a Canadian leader in the category of medical devices for home use, and has successfully launched several blood glucose monitoring systems into the Canadian market over the years. Health Canada is Canada's federal department responsible for helping Canadians maintain their health and the Health Canada approval is a major milestone representing the first sales of Dario in North America.
The Next Big Players in Mobile Health: Apple Watch and Dario
ACCESSWIRE - Mon May 11, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / May 11, 2015 / The market for mobile health monitoring and diagnostics is projected to reach $8 billion by 2019. Two key players in this market are Apple with its Apple Watch and LabStyle Innovations (OTCQB: DRIO), maker of the Dario Diabetes Management System. This emerging market for small, sleek and often wearable devices that function as mobile healthcare diagnostic devices was estimated at a mere $650 million in 2012. It has been dominated by cardiac monitors that work in conjunction with smart phones. According to Transparency Market Research, the market is expected to grow at a CAGR of 43%, led by growth in the mobile glucose monitoring segment. This is where LabStyle comes in with the Dario.
LabStyle Innovations Launches Online Store for Dario Diabetes Management Solution
PR Newswire - Thu May 07, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported it has opened its first ecommerce store for the Dario Smart meter and Dario accessories. The eShop serves the Israeli market, where the Dario Management Solution was launched in July 2014 following approval from the Israeli Ministry of Health. The Dario has received wide commendations and endorsements from both the medical community and the population of patients in Israel. The shop serves as an excellent channel for LabStyle to sell to people with diabetes and engage with them directly.
LabStyle Innovations to Deliver Poster Presentation at American Diabetes Association's 75th Scientific Sessions on June 5-9, 2015 in Boston
PR Newswire - Wed Apr 22, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) Diabetes Management Solution, today reported that the American Diabetes Association (ADA) has selected the Company's abstract titled, "Performance of Dario Blood Glucose Monitoring System Evaluated in a Clinical Study in Compliance with the New ISO 15197:2013 Standard," as a Late Breaking Poster Presentation at the ADA's 75th Anniversary Scientific Sessions.
Penny Stocks Research for ForeverGreen, FutureWorld, LabStyle Innovations, Root9b, TANARIS POWER, and Innovative Product Opportunities
PR Newswire - Fri Apr 17, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: ForeverGreen (OTCMKTS:FVRG), FutureWorld (OTCMKTS:FWDG), LabStyle Innovations (OTCMKTSRIO), Root9b (OTCMKTS:RTNB), TANARIS POWER (OTCBB:TPHX), and Innovative Product Opportunities (OTCMKTS:IPRU).
Global Rollout of LabStyle Innovations' Dario(TM) Diabetes Management Platform Brings $12 Billion Market Into the Digital Age
ACCESSWIRE - Thu Apr 09, 12:39PM CDT
NEW YORK, NY / ACCESSWIRE / April 9, 2015 / Israel-based LabStyle Innovations Corp. (OTCQB: DRIO) combines a smart phone with the need to manage a disease that is reaching epidemic proportions - namely diabetes - and what you get? A block buster product that is simple and elegant that uses the patients' own smart phone to monitor and manage diabetes.
LabStyle Innovations Announces 2014 Year End Results and Reports First Time Revenues from Global Rollout of Dario
PR Newswire - Wed Mar 25, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, reported that it has published its financial and operational results for the year ended December 31, 2014 and in connection therewith is providing an update on recent corporate achievements and anticipated milestones for 2015.
LabStyle Innovations Submits Data to U.S. FDA from Successfully Concluded 368 Patient Clinical Study of Dario Diabetes Management Solution for 510(k) Marketing Clearance
PR Newswire - Tue Mar 24, 8:45AM CDT
LabStyle Innovations Corp. (DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported that it has submitted new data to the U.S. Food and Drug Administration for its 510(k) application after successfully concluding a 368 patient User Performance Study on Dario. The study results showed that usability of the Dario Diabetes Management Solution is simple and intuitive. Data from the study indicates that the Dario(TM) Blood Glucose Monitoring System is highly comparable to its predicate device and in fact surpassed other glucose meters. Dario delivers accuracy that exceeds the minimum new stringent guidance of the ISO 15197:2013.
LabStyle Innovations Announces Successful Results from User Performance Evaluation Study to Support 510(k) Application and Announces Appointment of VP Regulatory
PR Newswire - Wed Mar 18, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported that it has concluded a 368 patient user performance study on the Dario. The results showed that usability of the Dario Diabetes Management Solution is simple and intuitive. The accuracy of Dario has proven to surpass other glucose meters and delivers accuracy that exceeds the minimum new stringent guidance of the ISO 15197:2013.
LabStyle Innovations enters into tele-care partnership with Israel's Maccabi Healthcare for remote support platform for diabetes
M2 - Fri Jan 23, 8:03PM CST
Diabetes management company LabStyle Innovations (OtherOTCRIO) disclosed on Thursday a partnership agreement to implement its comprehensive Dario digital suite for patients and professionals remote proactive care in Israel through Maccabi Healthcare.
LabStyle Innovations Announces HMO Tele-Care Partnership Agreement
PR Newswire - Thu Jan 22, 8:05AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported that it has signed a partnership agreement with Israel's leading healthcare HMO; Maccabi Healthcare to implement its comprehensive Dario(TM) digital suite for patients and professionals remote proactive care.
LabStyle Innovations Appoints Zvi Ben-David as New Chief Financial Officer
PR Newswire - Thu Jan 08, 8:05AM CST
LabStyle Innovations Corp. (OTCQBRIO), developer of the Dario(TM) Diabetes Management Solution, announced today that Zvi Ben-David will be joining LabStyle as the company's new Chief Financial Officer, Treasurer and Secretary effective immediately.
LabStyle Innovations Awarded Reimbursement Status in Australia for the Dario(TM) Smart Meter Strips
PR Newswire - Wed Dec 03, 8:05AM CST
LabStyle Innovations Corp. (OTCQB: DRIO) the maker of the Dario(TM) smart meter for diabetics announced today that it has been granted reimbursement status for its Dario(TM) blood glucose test strips to be utilized together with the patented Dario(TM) smart meter in Australia. This achievement marks another milestone in the continuing worldwide roll out of Dario(TM).
LabStyle Innovations Announces Two Board Appointments
PR Newswire - Mon Nov 24, 8:05AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that Dr. Peter Kash and Ms. Hila Karah have been appointed to serve on the company's Board of Directors.
LabStyle Innovations Announces 2014 Third Quarter Results and Provides Business Update
PR Newswire - Fri Nov 14, 8:15AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported its financial and operational results for the three month period ending September 30, 2014 and provided an update on recent corporate achievements and anticipated milestones for the remainder of 2014 and 2015.
LabStyle Innovations Common Stock to Resume Trading Under the Symbol "DRIO"
PR Newswire - Wed Nov 05, 8:15AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that its common stock will resume trading on the OTCQB Market under the symbol "DRIO."
LabStyle Innovations implements one for five reverse stock split
M2 - Mon Oct 06, 7:20AM CDT
Diabetes management solution LabStyle Innovations (Other OTCRIO) reported on Monday the launch of a one-for-five reverse common stock split at 9:00 eastern standard time.
LabStyle Innovations Implements 1-for-5 Reverse Stock Split
PR Newswire - Mon Oct 06, 5:00AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that effective at 9:00 a.m. eastern standard time on October 6, 2014, the company will implement a 1-for-5 reverse stock split of the company's common stock.
LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing
PR Newswire - Tue Sep 23, 3:05PM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that it has closed a $4.2 million private placement offering consisting of shares of preferred stock and warrants. No placement agent was used for this financing. After estimated offering expenses, LabStyle expects to secure net proceeds of approximately $4.1 million from this financing.
LabStyle Innovations Announces 2015 First Quarter Results
PR Newswire - Fri May 15, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, reported its financial and operational results for the three-month period ended March 31, 2015 and provided an update on recent corporate achievements.
LabStyle Innovations Receives Health Canada Approval for Commercialization of the Dario Diabetes Management Solution
PR Newswire - Thu May 14, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, has announced today that it has been granted Health Canada approval to market and sell Dario(TM) in Canada through their exclusive distributor in Canada Auto Control Medical Inc. ("ACM"
. ACM is a Canadian leader in the category of medical devices for home use, and has successfully launched several blood glucose monitoring systems into the Canadian market over the years. Health Canada is Canada's federal department responsible for helping Canadians maintain their health and the Health Canada approval is a major milestone representing the first sales of Dario in North America. The Next Big Players in Mobile Health: Apple Watch and Dario
ACCESSWIRE - Mon May 11, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / May 11, 2015 / The market for mobile health monitoring and diagnostics is projected to reach $8 billion by 2019. Two key players in this market are Apple with its Apple Watch and LabStyle Innovations (OTCQB: DRIO), maker of the Dario Diabetes Management System. This emerging market for small, sleek and often wearable devices that function as mobile healthcare diagnostic devices was estimated at a mere $650 million in 2012. It has been dominated by cardiac monitors that work in conjunction with smart phones. According to Transparency Market Research, the market is expected to grow at a CAGR of 43%, led by growth in the mobile glucose monitoring segment. This is where LabStyle comes in with the Dario.
LabStyle Innovations Launches Online Store for Dario Diabetes Management Solution
PR Newswire - Thu May 07, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported it has opened its first ecommerce store for the Dario Smart meter and Dario accessories. The eShop serves the Israeli market, where the Dario Management Solution was launched in July 2014 following approval from the Israeli Ministry of Health. The Dario has received wide commendations and endorsements from both the medical community and the population of patients in Israel. The shop serves as an excellent channel for LabStyle to sell to people with diabetes and engage with them directly.
LabStyle Innovations to Deliver Poster Presentation at American Diabetes Association's 75th Scientific Sessions on June 5-9, 2015 in Boston
PR Newswire - Wed Apr 22, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) Diabetes Management Solution, today reported that the American Diabetes Association (ADA) has selected the Company's abstract titled, "Performance of Dario Blood Glucose Monitoring System Evaluated in a Clinical Study in Compliance with the New ISO 15197:2013 Standard," as a Late Breaking Poster Presentation at the ADA's 75th Anniversary Scientific Sessions. Penny Stocks Research for ForeverGreen, FutureWorld, LabStyle Innovations, Root9b, TANARIS POWER, and Innovative Product Opportunities
PR Newswire - Fri Apr 17, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: ForeverGreen (OTCMKTS:FVRG), FutureWorld (OTCMKTS:FWDG), LabStyle Innovations (OTCMKTS
RIO), Root9b (OTCMKTS:RTNB), TANARIS POWER (OTCBB:TPHX), and Innovative Product Opportunities (OTCMKTS:IPRU). Global Rollout of LabStyle Innovations' Dario(TM) Diabetes Management Platform Brings $12 Billion Market Into the Digital Age
ACCESSWIRE - Thu Apr 09, 12:39PM CDT
NEW YORK, NY / ACCESSWIRE / April 9, 2015 / Israel-based LabStyle Innovations Corp. (OTCQB: DRIO) combines a smart phone with the need to manage a disease that is reaching epidemic proportions - namely diabetes - and what you get? A block buster product that is simple and elegant that uses the patients' own smart phone to monitor and manage diabetes.
LabStyle Innovations Announces 2014 Year End Results and Reports First Time Revenues from Global Rollout of Dario
PR Newswire - Wed Mar 25, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, reported that it has published its financial and operational results for the year ended December 31, 2014 and in connection therewith is providing an update on recent corporate achievements and anticipated milestones for 2015.
LabStyle Innovations Submits Data to U.S. FDA from Successfully Concluded 368 Patient Clinical Study of Dario Diabetes Management Solution for 510(k) Marketing Clearance
PR Newswire - Tue Mar 24, 8:45AM CDT
LabStyle Innovations Corp. (DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported that it has submitted new data to the U.S. Food and Drug Administration for its 510(k) application after successfully concluding a 368 patient User Performance Study on Dario. The study results showed that usability of the Dario Diabetes Management Solution is simple and intuitive. Data from the study indicates that the Dario(TM) Blood Glucose Monitoring System is highly comparable to its predicate device and in fact surpassed other glucose meters. Dario delivers accuracy that exceeds the minimum new stringent guidance of the ISO 15197:2013.
LabStyle Innovations Announces Successful Results from User Performance Evaluation Study to Support 510(k) Application and Announces Appointment of VP Regulatory
PR Newswire - Wed Mar 18, 8:05AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported that it has concluded a 368 patient user performance study on the Dario. The results showed that usability of the Dario Diabetes Management Solution is simple and intuitive. The accuracy of Dario has proven to surpass other glucose meters and delivers accuracy that exceeds the minimum new stringent guidance of the ISO 15197:2013.
LabStyle Innovations enters into tele-care partnership with Israel's Maccabi Healthcare for remote support platform for diabetes
M2 - Fri Jan 23, 8:03PM CST
Diabetes management company LabStyle Innovations (OtherOTC
RIO) disclosed on Thursday a partnership agreement to implement its comprehensive Dario digital suite for patients and professionals remote proactive care in Israel through Maccabi Healthcare. LabStyle Innovations Announces HMO Tele-Care Partnership Agreement
PR Newswire - Thu Jan 22, 8:05AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported that it has signed a partnership agreement with Israel's leading healthcare HMO; Maccabi Healthcare to implement its comprehensive Dario(TM) digital suite for patients and professionals remote proactive care.
LabStyle Innovations Appoints Zvi Ben-David as New Chief Financial Officer
PR Newswire - Thu Jan 08, 8:05AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) Diabetes Management Solution, announced today that Zvi Ben-David will be joining LabStyle as the company's new Chief Financial Officer, Treasurer and Secretary effective immediately. LabStyle Innovations Awarded Reimbursement Status in Australia for the Dario(TM) Smart Meter Strips
PR Newswire - Wed Dec 03, 8:05AM CST
LabStyle Innovations Corp. (OTCQB: DRIO) the maker of the Dario(TM) smart meter for diabetics announced today that it has been granted reimbursement status for its Dario(TM) blood glucose test strips to be utilized together with the patented Dario(TM) smart meter in Australia. This achievement marks another milestone in the continuing worldwide roll out of Dario(TM).
LabStyle Innovations Announces Two Board Appointments
PR Newswire - Mon Nov 24, 8:05AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that Dr. Peter Kash and Ms. Hila Karah have been appointed to serve on the company's Board of Directors.
LabStyle Innovations Announces 2014 Third Quarter Results and Provides Business Update
PR Newswire - Fri Nov 14, 8:15AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today reported its financial and operational results for the three month period ending September 30, 2014 and provided an update on recent corporate achievements and anticipated milestones for the remainder of 2014 and 2015.
LabStyle Innovations Common Stock to Resume Trading Under the Symbol "DRIO"
PR Newswire - Wed Nov 05, 8:15AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that its common stock will resume trading on the OTCQB Market under the symbol "DRIO."
LabStyle Innovations implements one for five reverse stock split
M2 - Mon Oct 06, 7:20AM CDT
Diabetes management solution LabStyle Innovations (Other OTC
RIO) reported on Monday the launch of a one-for-five reverse common stock split at 9:00 eastern standard time. LabStyle Innovations Implements 1-for-5 Reverse Stock Split
PR Newswire - Mon Oct 06, 5:00AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that effective at 9:00 a.m. eastern standard time on October 6, 2014, the company will implement a 1-for-5 reverse stock split of the company's common stock.
LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing
PR Newswire - Tue Sep 23, 3:05PM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that it has closed a $4.2 million private placement offering consisting of shares of preferred stock and warrants. No placement agent was used for this financing. After estimated offering expenses, LabStyle expects to secure net proceeds of approximately $4.1 million from this financing.
